Why the study?
Randomized controlled trials have established the role of drug-coated balloons for in-stent restenosis and small-vessel coronary artery disease, but their role for de novo large-vessel disease remains not well established.
Population
Patients with de novo large-vessel coronary artery disease
Comparison
Drug-coated balloons vs drug-eluting stents
Design
Updated meta-analysis using a random-effects model
Answers are grounded in this paper and cite their sources.
Meta-analysis shows reduced target revascularization with drug-coated balloons compared to drug-eluting stents in large coronary arteries, suggesting balloons are a viable alternative.
Randomized controlled trials have established the role of drug-coated balloon (DCB) for in-stent restenosis and small-vessel coronary artery disease. However, the role of DCB for large-vessel disease (LVD) remains not well established. Electronic databases were searched for studies comparing the clinical outcomes with DCB versus drug-eluting stents (DES) for de novo LVD. The primary outcome was target lesion revascularization (TLR). The secondary endpoints included cardiac mortality, all-cause mortality, myocardial infarction, and major adverse cardiac events (MACE). The angiographic outcomes were late lumen loss (LLL) and acute lumen gain. Summary estimates were pooled using a random-effects model. The pooled analysis showed lower TLR with DCB than DES (2.3% vs. 4.0%; OR = 0.58, 95% CI 0.35–0.98). DCB was associated with lower LLL (MD = − 0.18, 95% CI − 0.30 to − 0.10), whereas DES was associated with greater acute lumen gain (MD = − 0.52, 95% CI − 0.69 to − 0.34). There was no significant difference in MACE, cardiac mortality, all-cause mortality, or myocardial infarction, with pooled ORs (95% CIs) of 0.96 (0.54–1.70), 0.68 (0.37–1.26), 1.05 (0.77–1.43), and 1.05 (0.57–1.92), respectively. Among patients with LVD, DCB might be a reasonable alternative to DES. Additional randomized trials with longer follow-up are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Elazab et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: